For a safe treatment of the acute phase of ischemic stroke

Acticor Biotech is a clinical stage biotechnology company, founded in 2013, spin-off from the INSERM [French National Institute of Health and Medical Research], developing an innovative drug for the treatment of acute thrombotic diseases, including the acute phase of ischemic stroke.

The drug candidate of Acticor Biotech, glenzocimab (ACT017) is evaluated in the ACTIMIS Trial (NCT03803007) an international, multi-center phase 1b/2a clinical study to assess the safety of glenzocimab in Acute Ischemic Stroke as an add-on therapy to the Standard of Care.

In 2020, rising to respond to the challenge of global COVID-19 pandemic, Acticor Biotech initiated a phase 2 international clinical study (GARDEN, NCT04659109), assessing glenzocimab in the treatment of acute respiratory distress syndrome (ARDS) in SARS-Cov-2 infected patients.

Learn more on Acticor Biotech

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Paris, July 22, 2021 – Acticor Biotech, a clinical stage biotechnology company developing an innovative drug for the acute phase of ischemic stroke and thrombotic diseases, today announces the completion of recruitment in GARDEN, its phase 2 clinical study on the use of glenzocimab, a novel humanized monoclonal antibody fragment, in patients with COVID-19- induced […]
Read more

Strong market potential

Unmeet medical needs

13.7 Million strokes in the world

In 2016, 13.7 million strokes occurred in the world. Each year, around one million patients in Europe experience a stroke and approximately 800,000 in the USA (one every 40 seconds). In Europe, the Health Economics Research Centre of Oxford has estimated that incidence of stroke will rise of 34% by 2035.

Learn more

2nd Cause of Death

Stroke is the 2nd cause of death worlwide with an estimated 5.5 millions deaths in 2016 and a leading cause of acquired disabilities in adults.

Learn more

Major Economic Impact

In the USA stroke-related  costs were 103 billion dollars (2016). In the EU countries, the total annual costs of stroke is estimated at 60 billion euros (2017).

Learn more

Our aim: a drug candidate
with unique benefits

  • Unmeet medical needs in acute ischemic stroke

    Current pharmaceutical treatment of stroke are not fully satisfactory. Around 15% of patients can be treated with thrombolysis (alteplase) during the first hours after symptoms onset (4,5 hours in Europe, 3 hours in USA). Mechanical thrombectomy used since 2015 has demonstrated a 50% efficacy but only in a subpopulation of patients.

  • A first-in class antithrombotic drug

    Glenzocimab: an antithrombotic agent with limited bleeding risk. Glenzocimab development is initially conducted as an add-on therapy to the approved standard of care in the acute phase of Ischemic Stroke.

  • Novel therapeutic target

    Glenzocimab is directed against a novel target of major interest, platelet glycoprotein VI (GPVI) and inhibits its action. Activation of GPVI on the surface of platelets triggers platelet aggregation, the recruitment of additional platelets and results in activity that promotes coagulation. Additionally, GPVI plays a minor role in haemostasis, thus its inhibition will not cause hemorrhage.

News & Media

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Paris, July 22, 2021 – Acticor Biotech, a clinical stage biotechnology company developing an innovative drug for the acute phase of ischemic stroke and thrombotic diseases, today announces the completion of recruitment in GARDEN, its phase 2 clinical study on the use of glenzocimab, a novel humanized monoclonal antibody fragment, in patients with COVID-19- induced […]
Read more

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Paris, July 1st, 2021 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, today announces the end of recruitment in ACTIMIS, its phase 1b/2a study with glenzocimab (ACT017), a novel humanized monoclonal antibody fragment for use in patients with acute ischemic stroke. ACTIMIS (NCT03803007) is a multinational, multicenter, […]
Read more

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Paris, June 15 th, 2021 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers. Mrs Sophie Binay and Mr […]
Read more